(Q24672903)

2

0 references

D W Bonhaus

3

0 references

L G Johnson

4

0 references

K Lee

5

0 references

S Porter

6

0 references

K Walker

7

0 references

G Martinez

8

0 references

R M Eglen

9

0 references

R L Whiting

10

0 references

S S Hegde

British Journal of Pharmacology

11

0 references

language of work or name

English

0 references

publication date

August 1997

0 references

published in

0 references

volume

121

0 references

issue

8

0 references

page(s)

1803-9

0 references

cites work

Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine- and dopamine- -hydroxylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

Assessment of sympathetic nervous function in humans from noradrenaline plasma kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

Direct evidence from intraneural recordings for increased central sympathetic outflow in patients with heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

Expression of human dopamine beta-hydroxylase in Drosophila Schneider 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

Therapeutic strategies and neurohormonal control in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

Pathophysiologic and pharmacologic rationales for clinical management of chronic heart failure with beta-blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

BRL 8242 (2-[2-benzimidazolyl]-amino-2-imidazoline dihydrochloride), a new inhibitor of dopamine-β-hydroxylase with antihypertensive activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Beta-blockers in heart failure: promising or proved?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

A time-resolved assay of dopamine beta-hydroxylase activity utilizing high-pressure liquid chromatography

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

The effect of disulfiram on the biosynthesis of catecholamines during exposure of rats to cold

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

The Role of ??-Blockers in the Treatment of Cardiomyopathy and Ischaemic Heart Failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Norepinephrine spillover to plasma in patients with congestive heart failure: evidence of increased overall and cardiorenal sympathetic nervous activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Activity of the sympathetic nervous system and renin-angiotensin system assessed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Pharmacology of fusaric acid in man.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Neuroendocrine changes in heart failure and their clinical relevance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Beta-adrenergic blockers and survival in heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Plasma norepinephrine in congestive heart failure

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021

Labelling of 5-hydroxytryptamine3 receptors with a novel 5-HT3 receptor ligand, [3H]RS-42358-197.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BJP.0701315

7 January 2021